Shell stock faces Kazakhstan pause and auditor switch — what to watch for SHEL shares next week
7 February 2026
2 mins read

Shell stock faces Kazakhstan pause and auditor switch — what to watch for SHEL shares next week

London, Feb 7, 2026, 07:53 GMT — Market shut.

  • Shell shares ticked up Friday, capping a turbulent week of earnings for oil majors.
  • CEO Wael Sawan said the company plans to halt new investments in Kazakhstan for now, citing ongoing legal disputes.
  • Buybacks, reserves, and those looming dividend dates are all on traders’ radar.

Shell is hitting the brakes on new investments in Kazakhstan amid ongoing legal fights with the government, Chief Executive Wael Sawan said. The move injects a new layer of risk for the oil major, just as investors look toward next week.

Shell finished Friday’s session at 2,774.5 pence, gaining 0.18% in London trading. The stock moved between 2,741.5 and 2,792.5 pence on the day. 1

Timing’s crucial here. Shell just turned in a profit miss and stuck with its buyback. Now, a headline reopens questions about its geopolitical and legal risks—precisely the baggage investors would rather ignore while crude prices carry the load.

Kazakhstan isn’t exactly a sideshow. The wrangling involves two major flagship fields—disputes here could end up influencing just how hard Shell leans in on capital spending for large, long-term projects in the coming years.

Kazakhstan is pursuing arbitration against the developers at Kashagan and Karachaganak, seeking $13 billion and $3.5 billion in contested costs. Sawan told analysts these legal battles are weighing on Shell’s willingness to put more money into Kazakhstan, saying the company wants “better line of sight” before moving forward. 2

Shell shares dropped 3.4% Thursday after the company’s fourth-quarter earnings fell short of forecasts, knocking London energy stocks down with them. 3

Shell posted a fourth-quarter net profit of $3.3 billion, coming in short of the $3.5 billion adjusted earnings forecast from its own poll—a figure the company favors as its main profit metric. The oil major is keeping its $3.5 billion quarterly share buyback intact and bumped its dividend 4% to $0.372 per share. Chief Financial Officer Sinead Gorman called the payout range “sacrosanct.” RBC analysts highlighted a slide in Shell’s reserve life, now at 7.8 years compared to 8.9 years previously, potentially inviting more scrutiny of the company’s M&A plans. CEO Wael Sawan said recent acquisitions and efforts in the field have mostly covered a projected 100,000–200,000 boed shortfall (barrels of oil equivalent per day) anticipated by decade’s end. 4

RBC is dialing back its outlook on the stock. Analyst Biraj Borkhataria slashed Shell to “Sector Perform” from “Outperform” and lowered his price target to 3,200p, down from 3,600p. He pointed to a rare “double miss” on both guidance and results, with added worries about Shell’s depth of resources. 5

Governance keeps surfacing. Shell tapped PwC to succeed EY as its auditor starting in 2027, after a tender process prompted by questions over audit partner rotation rules. The company also plans to revise its 2023 and 2024 annual reports, but the financial statements themselves won’t change. 6

Investors are also watching LNG developments, with Shell in the spotlight. According to sources cited by Reuters, Atlantic LNG in Trinidad will take its Train 4 unit offline for maintenance starting May 4, with work expected to last 45 to 50 days. That outage could knock out more than 600,000 metric tons of output. Both Shell and BP each hold a 45% stake in the facility. 7

Shell’s buyback continues quietly. On Feb. 6, the company acquired and plans to cancel 1,637,748 shares across London and European exchanges, with Morgan Stanley handling trades on its own discretion until May 1. 8

Still, there’s no shortage of risk. A steeper hit from Kazakhstan arbitration, sharper drops in oil and gas, or further softness in chemicals and trading could all put pressure on buybacks and dividends. Any wobble in payout discipline, and the shares will likely feel it.

The dividend timeline is on deck. Shell’s ordinary shares are set to go ex-dividend Feb. 19—pick up shares after that, no dividend. Payment’s scheduled for March 30. For U.S. ADS holders, ex-dividend lands Feb. 20. More details at 9 .

Stock Market Today

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

7 February 2026
New York, Feb 7, 2026, 09:34 EST — Market closed. Alphabet’s non-voting Class C shares (GOOG) closed down 2.48% at $323.10 on Friday, extending a pullback after the Google parent flagged a sharp jump in spending tied to artificial intelligence. 1 With U.S. markets shut for the weekend, the near-term test is whether investors keep treating Big Tech’s AI build-out as a cost problem before it becomes a growth story. A Reuters review of the week’s trading showed fresh jitters around 2026 outlays across the sector, and SanJac Alpha chief investment officer Andrew Wells said the AI trade “got too
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B
Previous Story

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Anglo American share price slips as BofA turns neutral after copper outlook cut
Next Story

Anglo American share price slips as BofA turns neutral after copper outlook cut

Go toTop